Daniel Peters
@DPetersMD
Leukemia Trialist | Assist. Prof. @MCG_AUG @GACancerCenter| @UNCHemeOnc trained | Former Osler Resident @OslerResidency | Forever South Carolina Gamecock @UofSC
Wrapped up a great first week as BMT & Cell Therapy faculty @GACancerCenter @MCG_AUG. Enjoying the new office, meeting the team, and marveling at both the state-of-the-art core facilities and beautiful campus. It makes it easy to feel inspired.💡Let’s get to work!
At some point, someone invested in us. Now it’s our turn. Join me in supporting the #Fight4Hematology and help secure the future of hematology research and care. @ASH_hematology @b_avalos_MD @BloodGlobalHema @BloodPortfolio donate.hematology.org/s/
Fantastic overview of a VERY broad and controversial topic in AML therapy by @LeukDocJZ @_MDEducation AML-ALL US Focus Meeting.
I think ddx state could be the next critical axis for stratifying AML. Beyond mutational data, this layer may guide tx selection, predict drug response, and one day serve as the basis for enrollment in ddx state–targeted trials. Inspiring work! @livius_tacitus
In the Spotlight: Putting AML Differentiation States on the BoneMarrowMap brnw.ch/21wTXqZ @livius_tacitus
Leading the ongoing trial in older adults with NPM1-mutant or KMT2A-rearranged AML, @LeukDocJZ reports the addition of oral revumenib to azacitidine + venetoclax is safe and drives high remission rates, paving the way for a pivotal phase III. #AML ascopost.com/news/june-2025…
#MDSsm docs- Phase 3 VERONA Trial for Higher-Risk MDS for Aza+Ven was not positive for its end point of OS . Does this mean you will 👇🏾@Dr_AmerZeidan @MikkaelSekeres @Daver_Leukemia @DavidSteensma @MdSwoboda @LeukDocJZ